Concepts (321)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Polymorphism, Single Nucleotide | 6 | 2025 | 52 | 1.750 |
Why?
|
| Female | 26 | 2025 | 2816 | 1.520 |
Why?
|
| Myelodysplastic Syndromes | 3 | 2024 | 4 | 1.420 |
Why?
|
| Humans | 30 | 2025 | 5485 | 1.290 |
Why?
|
| Male | 22 | 2025 | 2770 | 1.280 |
Why?
|
| Neoplasms | 3 | 2025 | 99 | 1.040 |
Why?
|
| Middle Aged | 12 | 2025 | 1100 | 0.970 |
Why?
|
| Single-Domain Antibodies | 1 | 2025 | 1 | 0.970 |
Why?
|
| Fish Diseases | 2 | 2025 | 2 | 0.960 |
Why?
|
| Quantitative Trait Loci | 2 | 2025 | 5 | 0.960 |
Why?
|
| Dendrimers | 1 | 2025 | 6 | 0.960 |
Why?
|
| Polylysine | 1 | 2025 | 6 | 0.960 |
Why?
|
| DNA Fingerprinting | 2 | 2024 | 3 | 0.960 |
Why?
|
| Adult | 14 | 2025 | 1687 | 0.950 |
Why?
|
| Cannabis | 2 | 2024 | 20 | 0.910 |
Why?
|
| Aged | 10 | 2025 | 860 | 0.840 |
Why?
|
| Animals | 11 | 2025 | 1817 | 0.810 |
Why?
|
| Hordeum | 2 | 2025 | 2 | 0.730 |
Why?
|
| Progesterone | 2 | 2025 | 4 | 0.720 |
Why?
|
| Registries | 3 | 2024 | 24 | 0.710 |
Why?
|
| Breast Neoplasms | 2 | 2024 | 107 | 0.620 |
Why?
|
| Salmo salar | 2 | 2025 | 2 | 0.610 |
Why?
|
| Body Remains | 2 | 2024 | 2 | 0.600 |
Why?
|
| Microsatellite Repeats | 2 | 2024 | 8 | 0.600 |
Why?
|
| Genome-Wide Association Study | 2 | 2025 | 13 | 0.590 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2024 | 18 | 0.590 |
Why?
|
| Chromosome Mapping | 2 | 2024 | 13 | 0.590 |
Why?
|
| Biomass | 2 | 2025 | 21 | 0.530 |
Why?
|
| Animal Migration | 1 | 2025 | 1 | 0.490 |
Why?
|
| Animals, Wild | 1 | 2025 | 3 | 0.490 |
Why?
|
| Influenza in Birds | 1 | 2025 | 2 | 0.490 |
Why?
|
| Influenza A Virus, H5N1 Subtype | 1 | 2025 | 2 | 0.490 |
Why?
|
| Disease Resistance | 1 | 2025 | 1 | 0.490 |
Why?
|
| Interleukin-1 | 1 | 2025 | 1 | 0.490 |
Why?
|
| Asymptomatic Infections | 1 | 2025 | 2 | 0.490 |
Why?
|
| MADS Domain Proteins | 1 | 2025 | 1 | 0.490 |
Why?
|
| Ovule | 1 | 2025 | 1 | 0.490 |
Why?
|
| Bass | 1 | 2025 | 3 | 0.490 |
Why?
|
| Interleukins | 1 | 2025 | 3 | 0.490 |
Why?
|
| Gene Expression Regulation, Plant | 1 | 2025 | 3 | 0.490 |
Why?
|
| Whole Genome Sequencing | 1 | 2025 | 12 | 0.480 |
Why?
|
| Plant Proteins | 1 | 2025 | 7 | 0.480 |
Why?
|
| Quercus | 1 | 2025 | 1 | 0.480 |
Why?
|
| Genome, Plant | 1 | 2025 | 5 | 0.480 |
Why?
|
| Blepharoptosis | 1 | 2025 | 1 | 0.480 |
Why?
|
| Lymphatic Metastasis | 1 | 2025 | 1 | 0.480 |
Why?
|
| Salivary Gland Neoplasms | 1 | 2025 | 1 | 0.480 |
Why?
|
| Blinking | 1 | 2025 | 2 | 0.480 |
Why?
|
| Certolizumab Pegol | 1 | 2025 | 1 | 0.480 |
Why?
|
| Pharmacovigilance | 1 | 2025 | 2 | 0.480 |
Why?
|
| Ivermectin | 1 | 2024 | 1 | 0.480 |
Why?
|
| Copepoda | 1 | 2024 | 1 | 0.480 |
Why?
|
| Haplotypes | 1 | 2025 | 12 | 0.480 |
Why?
|
| Household Products | 1 | 2024 | 1 | 0.480 |
Why?
|
| Sulfuric Acids | 1 | 2024 | 1 | 0.480 |
Why?
|
| Drug Resistance | 1 | 2024 | 3 | 0.480 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 6 | 1 | 2024 | 1 | 0.480 |
Why?
|
| Reproductive Health | 1 | 2024 | 2 | 0.480 |
Why?
|
| Cystitis, Interstitial | 1 | 2024 | 1 | 0.480 |
Why?
|
| Hematology | 1 | 2024 | 1 | 0.480 |
Why?
|
| Mentors | 1 | 2024 | 8 | 0.480 |
Why?
|
| Hypertension, Pulmonary | 1 | 2024 | 3 | 0.480 |
Why?
|
| Pelvic Floor | 1 | 2024 | 2 | 0.480 |
Why?
|
| Patellar Ligament | 1 | 2024 | 1 | 0.480 |
Why?
|
| Natural Language Processing | 1 | 2024 | 6 | 0.480 |
Why?
|
| Herbicides | 1 | 2024 | 3 | 0.480 |
Why?
|
| Blood Transfusion | 1 | 2024 | 1 | 0.480 |
Why?
|
| Pregnancy Complications | 1 | 2025 | 11 | 0.480 |
Why?
|
| Intrinsically Disordered Proteins | 1 | 2024 | 2 | 0.480 |
Why?
|
| Cross-Over Studies | 1 | 2025 | 31 | 0.480 |
Why?
|
| Ventricular Remodeling | 1 | 2024 | 2 | 0.480 |
Why?
|
| Zea mays | 1 | 2024 | 3 | 0.480 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2024 | 5 | 0.470 |
Why?
|
| Achilles Tendon | 1 | 2024 | 4 | 0.470 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2024 | 7 | 0.470 |
Why?
|
| Ankle Joint | 1 | 2024 | 7 | 0.470 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2024 | 3 | 0.470 |
Why?
|
| Surgical Wound Infection | 1 | 2024 | 2 | 0.470 |
Why?
|
| Guideline Adherence | 1 | 2024 | 6 | 0.470 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2024 | 3 | 0.470 |
Why?
|
| Faculty, Medical | 1 | 2024 | 6 | 0.470 |
Why?
|
| Muscle Strength | 1 | 2024 | 9 | 0.470 |
Why?
|
| Electronic Health Records | 1 | 2024 | 18 | 0.470 |
Why?
|
| Pyramidal Tracts | 1 | 2024 | 5 | 0.470 |
Why?
|
| Proportional Hazards Models | 1 | 2024 | 30 | 0.470 |
Why?
|
| Bone and Bones | 1 | 2024 | 17 | 0.470 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2024 | 20 | 0.470 |
Why?
|
| Receptors, Progesterone | 1 | 2024 | 12 | 0.470 |
Why?
|
| Neurosurgical Procedures | 1 | 2024 | 13 | 0.470 |
Why?
|
| Hemodynamics | 1 | 2024 | 18 | 0.470 |
Why?
|
| Reproduction | 1 | 2024 | 26 | 0.470 |
Why?
|
| Climate Change | 1 | 2024 | 21 | 0.470 |
Why?
|
| Phylogeny | 1 | 2025 | 66 | 0.460 |
Why?
|
| Carbon | 1 | 2024 | 18 | 0.460 |
Why?
|
| Lung Neoplasms | 1 | 2024 | 27 | 0.460 |
Why?
|
| Glucuronosyltransferase | 1 | 2024 | 30 | 0.460 |
Why?
|
| Medicaid | 1 | 2024 | 29 | 0.460 |
Why?
|
| Minority Groups | 1 | 2024 | 39 | 0.460 |
Why?
|
| Electromyography | 1 | 2024 | 47 | 0.460 |
Why?
|
| Veterans | 1 | 2024 | 24 | 0.460 |
Why?
|
| Machine Learning | 1 | 2024 | 39 | 0.450 |
Why?
|
| Medicare | 1 | 2024 | 79 | 0.450 |
Why?
|
| DNA | 1 | 2024 | 65 | 0.450 |
Why?
|
| Cell Proliferation | 1 | 2024 | 120 | 0.450 |
Why?
|
| Ecosystem | 1 | 2024 | 59 | 0.450 |
Why?
|
| Cardiovascular Diseases | 1 | 2024 | 44 | 0.450 |
Why?
|
| Sex Chromosomes | 1 | 2024 | 9 | 0.440 |
Why?
|
| Stroke | 1 | 2024 | 53 | 0.440 |
Why?
|
| Analgesics, Opioid | 1 | 2024 | 74 | 0.430 |
Why?
|
| Muscle, Skeletal | 1 | 2024 | 82 | 0.430 |
Why?
|
| Quality of Life | 1 | 2024 | 117 | 0.430 |
Why?
|
| Aged, 80 and over | 4 | 2025 | 321 | 0.420 |
Why?
|
| Signal Transduction | 1 | 2025 | 225 | 0.410 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2024 | 109 | 0.410 |
Why?
|
| Infant, Newborn | 4 | 2025 | 49 | 0.410 |
Why?
|
| Retrospective Studies | 4 | 2025 | 382 | 0.410 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2024 | 250 | 0.390 |
Why?
|
| Exercise | 1 | 2024 | 176 | 0.390 |
Why?
|
| Anti-Bacterial Agents | 1 | 2024 | 183 | 0.390 |
Why?
|
| Genotype | 3 | 2025 | 58 | 0.350 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2024 | 55 | 0.340 |
Why?
|
| Cell Line, Tumor | 2 | 2025 | 175 | 0.340 |
Why?
|
| Treatment Outcome | 3 | 2025 | 212 | 0.330 |
Why?
|
| Infant | 3 | 2025 | 87 | 0.290 |
Why?
|
| Child, Preschool | 3 | 2025 | 187 | 0.280 |
Why?
|
| Young Adult | 3 | 2025 | 852 | 0.260 |
Why?
|
| Hydroxyurea | 1 | 2025 | 1 | 0.240 |
Why?
|
| Antisickling Agents | 1 | 2025 | 2 | 0.240 |
Why?
|
| Crops, Agricultural | 1 | 2025 | 1 | 0.240 |
Why?
|
| Photosynthesis | 1 | 2025 | 2 | 0.240 |
Why?
|
| Oligopeptides | 1 | 2025 | 8 | 0.240 |
Why?
|
| Waist Circumference | 1 | 2025 | 8 | 0.240 |
Why?
|
| Anemia, Sickle Cell | 1 | 2025 | 10 | 0.240 |
Why?
|
| Menopause | 1 | 2025 | 6 | 0.240 |
Why?
|
| Drug Carriers | 1 | 2025 | 9 | 0.240 |
Why?
|
| Placenta | 1 | 2024 | 6 | 0.240 |
Why?
|
| Canada | 2 | 2024 | 5 | 0.240 |
Why?
|
| Estradiol | 1 | 2025 | 16 | 0.240 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2024 | 9 | 0.240 |
Why?
|
| Aldehyde Oxidase | 1 | 2024 | 1 | 0.240 |
Why?
|
| Drug Interactions | 1 | 2024 | 8 | 0.240 |
Why?
|
| Extracellular Matrix | 1 | 2025 | 14 | 0.240 |
Why?
|
| Picornaviridae | 1 | 2024 | 1 | 0.240 |
Why?
|
| Picornaviridae Infections | 1 | 2024 | 1 | 0.240 |
Why?
|
| Swine Diseases | 1 | 2024 | 1 | 0.240 |
Why?
|
| Immunodominant Epitopes | 1 | 2024 | 1 | 0.240 |
Why?
|
| Epitope Mapping | 1 | 2024 | 1 | 0.240 |
Why?
|
| Adiposity | 1 | 2025 | 19 | 0.240 |
Why?
|
| Capsid Proteins | 1 | 2024 | 3 | 0.240 |
Why?
|
| Polyethylene Glycols | 1 | 2025 | 28 | 0.240 |
Why?
|
| Mice | 2 | 2025 | 719 | 0.240 |
Why?
|
| Chromatin | 1 | 2024 | 7 | 0.240 |
Why?
|
| Polymerase Chain Reaction | 2 | 2024 | 38 | 0.240 |
Why?
|
| Prognosis | 2 | 2025 | 59 | 0.240 |
Why?
|
| Insulin | 1 | 2025 | 31 | 0.240 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2024 | 21 | 0.230 |
Why?
|
| Sequence Analysis, DNA | 2 | 2024 | 27 | 0.230 |
Why?
|
| Tumor Microenvironment | 1 | 2024 | 28 | 0.230 |
Why?
|
| Antibodies, Viral | 1 | 2024 | 14 | 0.230 |
Why?
|
| Body Mass Index | 1 | 2025 | 101 | 0.230 |
Why?
|
| Prospective Studies | 2 | 2024 | 132 | 0.230 |
Why?
|
| Parents | 1 | 2025 | 59 | 0.230 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2025 | 37 | 0.220 |
Why?
|
| Risk Factors | 2 | 2025 | 184 | 0.220 |
Why?
|
| Mice, Inbred C57BL | 1 | 2025 | 195 | 0.220 |
Why?
|
| Antineoplastic Agents | 1 | 2025 | 72 | 0.220 |
Why?
|
| Obesity | 1 | 2025 | 118 | 0.210 |
Why?
|
| Models, Biological | 1 | 2024 | 131 | 0.210 |
Why?
|
| Surveys and Questionnaires | 2 | 2024 | 277 | 0.210 |
Why?
|
| United States | 2 | 2024 | 522 | 0.190 |
Why?
|
| Child | 2 | 2025 | 657 | 0.180 |
Why?
|
| Carbon Dioxide | 2 | 2025 | 9 | 0.180 |
Why?
|
| Adolescent | 2 | 2025 | 806 | 0.180 |
Why?
|
| Pregnancy | 2 | 2025 | 103 | 0.170 |
Why?
|
| New Zealand | 1 | 2025 | 1 | 0.120 |
Why?
|
| Charadriiformes | 1 | 2025 | 1 | 0.120 |
Why?
|
| Islands | 1 | 2025 | 1 | 0.120 |
Why?
|
| Influenza A virus | 1 | 2025 | 3 | 0.120 |
Why?
|
| Genomic Structural Variation | 1 | 2025 | 1 | 0.120 |
Why?
|
| Epidemiological Monitoring | 1 | 2025 | 2 | 0.120 |
Why?
|
| Birds | 1 | 2025 | 5 | 0.120 |
Why?
|
| Lymphoid Tissue | 1 | 2025 | 1 | 0.120 |
Why?
|
| Sheep Diseases | 1 | 2025 | 1 | 0.120 |
Why?
|
| Encephalopathy, Bovine Spongiform | 1 | 2025 | 1 | 0.120 |
Why?
|
| PrPSc Proteins | 1 | 2025 | 1 | 0.120 |
Why?
|
| Edible Grain | 1 | 2025 | 1 | 0.120 |
Why?
|
| Prions | 1 | 2025 | 2 | 0.120 |
Why?
|
| Sheep | 1 | 2025 | 3 | 0.120 |
Why?
|
| Triticum | 1 | 2025 | 3 | 0.120 |
Why?
|
| Chromosomes, Plant | 1 | 2025 | 1 | 0.120 |
Why?
|
| United Kingdom | 1 | 2025 | 9 | 0.120 |
Why?
|
| Synteny | 1 | 2025 | 2 | 0.120 |
Why?
|
| Genes, Plant | 1 | 2025 | 4 | 0.120 |
Why?
|
| Multigene Family | 1 | 2025 | 5 | 0.120 |
Why?
|
| Lymph Nodes | 1 | 2025 | 2 | 0.120 |
Why?
|
| Reference Standards | 1 | 2025 | 13 | 0.120 |
Why?
|
| Cattle | 1 | 2025 | 20 | 0.120 |
Why?
|
| Survival Rate | 1 | 2025 | 16 | 0.120 |
Why?
|
| Molecular Sequence Annotation | 1 | 2025 | 12 | 0.120 |
Why?
|
| Neoplasm Invasiveness | 1 | 2025 | 9 | 0.120 |
Why?
|
| Abnormalities, Drug-Induced | 1 | 2025 | 1 | 0.120 |
Why?
|
| Japan | 1 | 2025 | 4 | 0.120 |
Why?
|
| Career Choice | 1 | 2024 | 1 | 0.120 |
Why?
|
| DNA Degradation, Necrotic | 1 | 2024 | 1 | 0.120 |
Why?
|
| Pregnancy Outcome | 1 | 2025 | 6 | 0.120 |
Why?
|
| Hydrochloric Acid | 1 | 2024 | 1 | 0.120 |
Why?
|
| Detergents | 1 | 2024 | 2 | 0.120 |
Why?
|
| Double-Blind Method | 1 | 2025 | 34 | 0.120 |
Why?
|
| Sodium Hypochlorite | 1 | 2024 | 3 | 0.120 |
Why?
|
| Eyelids | 1 | 2025 | 10 | 0.120 |
Why?
|
| Immersion | 1 | 2024 | 3 | 0.120 |
Why?
|
| Disinfectants | 1 | 2024 | 3 | 0.120 |
Why?
|
| Systematized Nomenclature of Medicine | 1 | 2024 | 2 | 0.120 |
Why?
|
| Cardiac Output | 1 | 2024 | 2 | 0.120 |
Why?
|
| Cardiac Catheterization | 1 | 2024 | 3 | 0.120 |
Why?
|
| Myalgia | 1 | 2024 | 1 | 0.120 |
Why?
|
| Fever | 1 | 2024 | 2 | 0.120 |
Why?
|
| Tranexamic Acid | 1 | 2024 | 1 | 0.120 |
Why?
|
| Dronabinol | 1 | 2024 | 1 | 0.120 |
Why?
|
| Transferases | 1 | 2024 | 1 | 0.120 |
Why?
|
| DNA, Plant | 1 | 2024 | 1 | 0.120 |
Why?
|
| Humulus | 1 | 2024 | 1 | 0.120 |
Why?
|
| Genotyping Techniques | 1 | 2024 | 1 | 0.120 |
Why?
|
| Electrophoresis, Capillary | 1 | 2024 | 2 | 0.120 |
Why?
|
| Neutropenia | 1 | 2024 | 2 | 0.120 |
Why?
|
| Anemia | 1 | 2024 | 2 | 0.120 |
Why?
|
| Antirheumatic Agents | 1 | 2025 | 6 | 0.120 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2024 | 5 | 0.120 |
Why?
|
| Carbon Sequestration | 1 | 2024 | 2 | 0.120 |
Why?
|
| Baltimore | 1 | 2024 | 1 | 0.120 |
Why?
|
| Current Procedural Terminology | 1 | 2024 | 1 | 0.120 |
Why?
|
| DNA, Mitochondrial | 1 | 2024 | 7 | 0.120 |
Why?
|
| District of Columbia | 1 | 2024 | 3 | 0.120 |
Why?
|
| Knee Joint | 1 | 2024 | 7 | 0.120 |
Why?
|
| Perioperative Care | 1 | 2024 | 1 | 0.120 |
Why?
|
| Neurosurgeons | 1 | 2024 | 2 | 0.120 |
Why?
|
| Muscle Contraction | 1 | 2024 | 12 | 0.120 |
Why?
|
| Fertility | 1 | 2024 | 8 | 0.120 |
Why?
|
| Rest | 1 | 2024 | 11 | 0.120 |
Why?
|
| Health Care Surveys | 1 | 2024 | 14 | 0.120 |
Why?
|
| Mentoring | 1 | 2024 | 13 | 0.120 |
Why?
|
| Program Evaluation | 1 | 2024 | 28 | 0.120 |
Why?
|
| Genetic Variation | 1 | 2025 | 36 | 0.120 |
Why?
|
| Databases, Factual | 1 | 2025 | 32 | 0.120 |
Why?
|
| Static Electricity | 1 | 2024 | 15 | 0.120 |
Why?
|
| Proteome | 1 | 2024 | 9 | 0.120 |
Why?
|
| Sepsis | 1 | 2024 | 4 | 0.120 |
Why?
|
| Oculomotor Muscles | 1 | 2025 | 15 | 0.120 |
Why?
|
| Prostheses and Implants | 1 | 2025 | 31 | 0.120 |
Why?
|
| Genomics | 1 | 2025 | 44 | 0.120 |
Why?
|
| Postoperative Complications | 1 | 2024 | 17 | 0.120 |
Why?
|
| Community Health Services | 1 | 2024 | 6 | 0.120 |
Why?
|
| Fatigue | 1 | 2024 | 13 | 0.120 |
Why?
|
| Practice Guidelines as Topic | 1 | 2024 | 20 | 0.120 |
Why?
|
| Protein Conformation | 1 | 2024 | 46 | 0.120 |
Why?
|
| Follow-Up Studies | 1 | 2025 | 97 | 0.120 |
Why?
|
| Cholesterol, LDL | 1 | 2024 | 8 | 0.120 |
Why?
|
| Hospitalization | 1 | 2024 | 38 | 0.120 |
Why?
|
| Heart Ventricles | 1 | 2024 | 25 | 0.120 |
Why?
|
| Risk Assessment | 1 | 2025 | 49 | 0.120 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2024 | 20 | 0.120 |
Why?
|
| Upper Extremity | 1 | 2024 | 15 | 0.120 |
Why?
|
| Transcranial Magnetic Stimulation | 1 | 2024 | 19 | 0.120 |
Why?
|
| Biological Evolution | 1 | 2025 | 34 | 0.120 |
Why?
|
| Exercise Test | 1 | 2024 | 43 | 0.120 |
Why?
|
| Soil | 1 | 2024 | 29 | 0.120 |
Why?
|
| Action Potentials | 1 | 2024 | 28 | 0.120 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2024 | 33 | 0.120 |
Why?
|
| Sex Factors | 1 | 2024 | 81 | 0.110 |
Why?
|
| Pilot Projects | 1 | 2024 | 119 | 0.110 |
Why?
|
| Cohort Studies | 2 | 2025 | 131 | 0.110 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2024 | 47 | 0.110 |
Why?
|
| Characiformes | 1 | 2024 | 1 | 0.110 |
Why?
|
| Time Factors | 1 | 2024 | 176 | 0.110 |
Why?
|
| Fishes | 1 | 2024 | 7 | 0.110 |
Why?
|
| Evolution, Molecular | 1 | 2025 | 68 | 0.110 |
Why?
|
| Genome | 1 | 2024 | 22 | 0.110 |
Why?
|
| Sex Determination Processes | 1 | 2024 | 11 | 0.110 |
Why?
|
| Opioid-Related Disorders | 1 | 2024 | 35 | 0.110 |
Why?
|
| Cross-Sectional Studies | 1 | 2024 | 284 | 0.100 |
Why?
|
| Brain | 1 | 2025 | 286 | 0.090 |
Why?
|
| Plant Breeding | 1 | 2025 | 1 | 0.060 |
Why?
|
| Chlorophyll | 1 | 2025 | 1 | 0.060 |
Why?
|
| Agriculture | 1 | 2025 | 6 | 0.060 |
Why?
|
| Ozone | 1 | 2025 | 3 | 0.060 |
Why?
|
| Plant Leaves | 1 | 2025 | 4 | 0.060 |
Why?
|
| Cartilage, Articular | 1 | 2025 | 1 | 0.060 |
Why?
|
| Weight Loss | 1 | 2025 | 8 | 0.060 |
Why?
|
| Chondrocytes | 1 | 2025 | 2 | 0.060 |
Why?
|
| Osteoarthritis, Knee | 1 | 2025 | 4 | 0.060 |
Why?
|
| Pregnancy Trimester, Third | 1 | 2024 | 2 | 0.060 |
Why?
|
| Cellular Senescence | 1 | 2025 | 14 | 0.060 |
Why?
|
| Clone Cells | 1 | 2024 | 4 | 0.060 |
Why?
|
| Stromal Cells | 1 | 2024 | 6 | 0.060 |
Why?
|
| Hypoglycemic Agents | 1 | 2025 | 15 | 0.060 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2024 | 4 | 0.060 |
Why?
|
| Unsupervised Machine Learning | 1 | 2024 | 2 | 0.060 |
Why?
|
| Antigen Presentation | 1 | 2024 | 7 | 0.060 |
Why?
|
| DNA Copy Number Variations | 1 | 2024 | 9 | 0.060 |
Why?
|
| Hepatocytes | 1 | 2024 | 13 | 0.060 |
Why?
|
| Cell Lineage | 1 | 2024 | 15 | 0.060 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2024 | 10 | 0.060 |
Why?
|
| Overweight | 1 | 2025 | 41 | 0.060 |
Why?
|
| Motion | 1 | 2024 | 22 | 0.060 |
Why?
|
| Antibodies, Monoclonal | 1 | 2024 | 19 | 0.060 |
Why?
|
| Swine | 1 | 2024 | 51 | 0.060 |
Why?
|
| Gene Regulatory Networks | 1 | 2024 | 35 | 0.060 |
Why?
|
| Amino Acid Sequence | 1 | 2024 | 54 | 0.060 |
Why?
|
| Macrophages | 1 | 2024 | 29 | 0.060 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2024 | 37 | 0.060 |
Why?
|
| Single-Cell Analysis | 1 | 2024 | 24 | 0.060 |
Why?
|
| Gene Expression Profiling | 1 | 2024 | 55 | 0.060 |
Why?
|
| Transcriptome | 1 | 2024 | 47 | 0.060 |
Why?
|
| Biomarkers | 1 | 2025 | 87 | 0.060 |
Why?
|
| Liver | 1 | 2024 | 51 | 0.060 |
Why?
|
| Models, Theoretical | 1 | 2024 | 78 | 0.060 |
Why?
|
| T-Lymphocytes | 1 | 2024 | 48 | 0.060 |
Why?
|
| Computer Simulation | 1 | 2024 | 187 | 0.050 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2024 | 116 | 0.050 |
Why?
|
| Mutation | 1 | 2024 | 137 | 0.050 |
Why?
|
| Disease Models, Animal | 1 | 2025 | 242 | 0.050 |
Why?
|